Curis Inc (CRIS) — Analysis Summary
Curis Inc (CRIS) has a market cap of $1.56M with year-over-year revenue growth of -13.4%. Net margin stands at -80.3%. The stock trades at a P/E ratio of -0.1.
Key Takeaways
- Revenue changed -13.4% year-over-year
- Net margin of -80.3%
- P/E ratio of -0.1
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, CRIS posted revenue growth of -13.4% and trades at a P/E of -0.1.
Curis Inc (CRIS)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Current ratio at 0.49x — severe short-term liquidity risk
Operating margin at -203.2% — severe operating losses
Net margin at -490.3% — losses exceed revenue (possible one-time charges)
Revenue fell 54.3% vs the prior period.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
24
Headquarters
LEXINGTON, MA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.